Blood enzyme accelerates bone aging in mice
A protein that accumulates in the bloodstream as we age directly damages bone tissue. Researchers found a way to selectively remove it, with measurable bone recovery as the result.
MMP9 is an enzyme normally involved in breaking down and remodelling tissue. As we age, MMP9 levels in the blood rise. Earlier research had suggested that high MMP9 concentrations contribute to bone inflammation and bone loss in older adults, but targeting it specifically without side effects elsewhere in the body was difficult.
The researchers described in the Fight Aging newsletter an approach using macrophages (immune cells that normally engulf foreign particles throughout the body) as a delivery vehicle. Via a lipid nanoparticle that mimics the surface features of cells undergoing programmed death, macrophages were prompted to produce an antibody that neutralises MMP9. This allowed the treatment to spread broadly through the body without requiring direct injection into bone tissue.
Macrophages as medical couriers
Using macrophages as producers of a therapeutic protein is a relatively new idea. Macrophages are present throughout the body and naturally produce large quantities of proteins. When directed via messenger RNA (a short-lived genetic instruction) to produce a specific antibody, they can distribute it broadly. The temporary instruction disappears over time, making the approach in principle reversible and controllable.
In aged mice, the treatment led to improved bone tissue quality. Bone density and structural characteristics improved measurably. Whether the same approach works in humans and is safe is unknown. The study was conducted in mice; clinical applications require extensive follow-up research.
Broader implications for longevity
This approach touches on two active themes in longevity research. First, bone aging (osteoporosis and loss of bone quality) is a major cause of disability in older adults. Second, the technique demonstrates how cell-based gene therapy, reprogramming the body’s own cells, offers possibilities that conventional drugs do not. Whether reducing MMP9 also provides benefits beyond bone is an open question.